Bristol-Myers Squibb Company (ETR:BRM)
Germany
· Delayed Price · Currency is EUR 55.33
+0.88 (1.62%)
Mar 31, 2025, 2:00 PM CET
ETR:BRM Revenue
In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B USD with 7.32% growth. Bristol-Myers Squibb Company had revenue of $12.34B in the quarter ending December 31, 2024, with 7.54% growth.
Revenue
$48.30B
Revenue Growth
+7.32%
P/S Ratio
n/a
Revenue / Employee
$1.42M
Employees
34,100
Market Cap
112.45B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
| Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
| Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
| Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
| Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck KGaA | 21.16B |
| Siemens Healthineers AG | 22.67B |
| Fresenius SE & Co. KGaA | 21.83B |
| Bayer Aktiengesellschaft | 46.61B |
| Sartorius Aktiengesellschaft | 3.38B |
| Fresenius Medical Care AG | 19.34B |
| Carl Zeiss Meditec AG | 2.08B |
| Fielmann Group AG | 2.16B |
Bristol-Myers Squibb Company News
- 1 day ago - Bristol-Myers Squibb (BMY) Among Cramer's Top Pharmaceutical Picks - GuruFocus
- 2 days ago - Bristol Myers Squibb gets positive CHMP opinion for neoadjuvant Opdivo and chemotherapy - Seeking Alpha
- 3 days ago - Bristol Myers Squibb gets CHMP positive opinion for Opdivo in multiple solid tumors - Seeking Alpha
- 3 days ago - Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1... - Wallstreet:Online
- 3 days ago - Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications - Benzinga
- 3 days ago - Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo (nivolumab) Across Multiple Solid Tumor Indications - Wallstreet:Online
- 5 days ago - 2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results - Benzinga
- 5 days ago - Bristol-Myers Squibb's Rally Is Well Deserved, Albeit Warranting A Downgrade To Hold - Seeking Alpha